Alnylam is committed to developing new, innovative medicines to treat diseases with high unmet medical need. A clinical trial involves research using human volunteers (trial participants, including healthy volunteers or patients), and is intended to answer specific questions about potential new treatments for certain diseases. These studies allow us to evaluate whether these potential new treatments are safe and effective.
If you have questions about our clinical trials, please contact us:
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
866-330-0326 (Toll-free within the United States)
+1 617-575-7400 (International)
Visit www.clinicaltrials.gov to learn more about eligibility to participate in a study, risks and benefits of study participation, the informed consent process, questions to ask when considering whether to participate in a study, and much more information regarding clinical trials.
We are committed to ensuring our clinical trial information is accessible to patients, health care providers, researchers and the general public as a way to further scientific discovery and advance public health.
Evaluating the efficacy and safety of patisiran in participants with ATTR amyloidosis with cardiomyopathy.
USA, Czech Republic, Denmark, Poland, Sweden, Argentina, Brazil, South Korea, Italy, Taiwan, UK, France, Japan, Portugal, Hong Kong, Australia, Mexico, Bulgaria
Evaluating the efficacy and safety of patisiran in participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression after liver transplant.
Italy, Sweden, Portugal, UK, Germany, Spain, France
Providing expanded access of patisiran to adults with hATTR amyloidosis with polyneuropathy who meet Karnofsky performance status and Polyneuropathy Disability (PND) score requirements.
Evaluating the long-term safety of patisiran in adults with hATTR amyloidosis with symptomatic polyneuropathy who participated in either the Phase 2 OLE study or the APOLLO study.
USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, UK
Evaluated the safety and efficacy of patisiran in adults with hereditary ATTR (hATTR) amyloidosis with symptomatic polyneuropathy (previously known as familial amyloidotic polyneuropathy [FAP]).
USA, Argentina, Australia, Brazil, Bulgaria, Canada, Cyprus, France, Germany, Italy, Japan, South Korea, Malaysia, Mexico, Netherlands, Portugal, Spain, Sweden, Taiwan, Turkey, UK
Evaluated the safety and efficacy of patisiran in adults with hATTR amyloidosis with symptomatic polyneuropathy who participated in the Phase 2 trial.
USA, Brazil, France, Germany, Portugal, Spain, Sweden
Evaluated the safety and efficacy of patisiran in adults with hATTR amyloidosis with symptomatic polyneuropathy.
USA, Brazil, France, Germany, Portugal, Spain, Sweden, Portugal
Long-term study of patients with transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis).
USA, Denmark, Sweden, Brazil, Italy, UK, France, Japan, Portugal, Spain, Netherlands, Germany, Israel
Evaluating the effect of givosiran (ALN-AS1) on the rate of porphyria attacks in patients with acute hepatic porphyria (AHP).
USA, Australia, Bulgaria, Canada, Denmark, Finland, France, Germany, Italy, Japan, South Korea, Mexico, Netherlands, Poland, Spain, Sweden, Taiwan, UK
A prospective observational study of adults with acute hepatic porphyria (AHP), including acute intermittent porphyria (AIP), variegate porphyria (VP), and hereditary coproporphyria (HCP), with recurrent attacks.
USA, Australia, Belgium, Bulgaria, Czech Republic, Finland, France, Germany, Italy, Israel, Mexico, Netherlands, Norway, Poland, South Africa, South Korea, Spain, Switzerland, Taiwan, UK
Evaluating the long-term safety and tolerability of givosiran in adults with acute intermittent porphyria (AIP), who participated in the Phase 2 trial.
USA, Sweden, UK
Evaluating the safety and tolerability of givosiran (ALN-AS1) in adults with acute intermittent porphyria (AIP).
USA, Sweden, UK
Evaluated the safety and efficacy of inclisiran in adults with elevated low density lipoprotein cholesterol (LDL-C).
UK
Evaluating the safety and efficacy of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1).
Israel, USA, France, Switzerland, Belgium, United Arab Emirates, Netherlands, Turkey, Australia, Jordan, Lebanon, UK
Evaluating the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
USA, UK, France, Germany, Netherlands, Switzerland, Israel, UAE
Evaluating the safety and efficacy of lumasiran in healthy volunteers and in patients with primary hyperoxaluria type 1 (PH1).
USA, France, UK, Germany, Israel, Netherlands, Jordan
Visit PH1trial.com for more information about the PH1 trial.
Evaluating the long-term safety and tolerability of lumasiran in patients with primary hyperoxaluria type 1.
France, Germany, Netherlands, UK, Israel
Evaluating the safety and efficacy of lumasiran in infants and young children with primary hyperoxaluria type 1 (PH1).
USA, UK, France, Germany, Israel
Evaluated the safety and efficacy of cemdisiran in healthy volunteers and adults with paroxysmal nocturnal hemoglobinuria (PNH).
Spain, UK
Evaluating the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
USA, Canada, Philippines, Spain, Sweden, UK, Singapore, France, Malaysia, Taiwan
Evaluating the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).
USA, Argentina, Bulgaria, France, Portugal, Malaysia, Cyprus, Germany, Japan, South Korea, Greece, Sweden, UK, Taiwan, Belgium, Mexico, Italy, Australia, Canada, Netherlands, Spain, Brazil
Evaluating the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR amyloidosis with cardiomyopathy).
USA, Latvia, Spain, France, Sweden, Lithuania, Portugal, Australia, Republic of Korea, Germany, Norway, UK, Israel, Hungary, Denmark, Ireland, Canada, Moldova, Slovenia, Austria, Poland, Netherlands, Belgium, Croatia, Scotland, Peru
Evaluating the safety and tolerability of single or multiple doses of ALN-AAT02 in participants with ZZ type alpha-1 antitrypsin deficiency (PiZZ) and biopsy-proven alpha-1 antitrypsin (AAT) deficiency-associated liver disease.
UK
Evaluating the safety and tolerability of ALN-AGT01 in patients with hypertension.
UK
An observational study to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease.
USA, UK, India, Malaysia, Mexico, Egypt
The purpose of this study is to evaluate the safety and tolerability of single ascending doses of ALN-HSD in healthy participants (Part A) and multiple doses of ALN-HSD in patients with NASH (Part B).
UK